| CRISPR-Cas9 gene editing for sickle cell disease and â-thalassemia H Frangoul, D Altshuler, MD Cappellini, YS Chen, J Domm, BK Eustace, ... New England Journal of Medicine 384 (3), 252-260, 2021 | 1229 | 2021 |
| A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with â-thalassemia MD Cappellini, A Cohen, A Piga, M Bejaoui, S Perrotta, L Agaoglu, ... Blood 107 (9), 3455-3462, 2006 | 932 | 2006 |
| Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran A Taher, H Isma¢eel, G Mehio, D Bignamini, A Kattamis, EA Rachmilewitz, ... Thrombosis and haemostasis 96 (10), 488-491, 2006 | 399 | 2006 |
| Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias MD Cappellini, J Porter, A El-Beshlawy, CK Li, JF Seymour, M Elalfy, ... haematologica 95 (4), 557, 2010 | 349 | 2010 |
| Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up MD Cappellini, M Bejaoui, L Agaoglu, D Canatan, M Capra, A Cohen, ... Blood, The Journal of the American Society of Hematology 118 (4), 884-893, 2011 | 251 | 2011 |
| A phase 3 trial of luspatercept in patients with transfusion-dependent â-thalassemia MD Cappellini, V Viprakasit, AT Taher, P Georgiev, KHM Kuo, T Coates, ... New England Journal of Medicine 382 (13), 1219-1231, 2020 | 245 | 2020 |
| Efficacy of deferasirox in reducing and preventing cardiac iron overload in â-thalassemia DJ Pennell, JB Porter, MD Cappellini, A El-Beshlawy, LL Chan, Y Aydinok, ... Blood, The Journal of the American Society of Hematology 115 (12), 2364-2371, 2010 | 234 | 2010 |
| Changing patterns in the epidemiology of â‐thalassemia A Kattamis, GL Forni, Y Aydinok, V Viprakasit European Journal of Haematology 105 (6), 692-703, 2020 | 214 | 2020 |
| The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major A Kattamis, I Papassotiriou, D Palaiologou, F Apostolakou, A Galani, ... haematologica 91 (6), 809-812, 2006 | 197 | 2006 |
| Recommendations regarding splenectomy in hereditary hemolytic anemias A Iolascon, I Andolfo, W Barcellini, F Corcione, L Garçon, L De Franceschi, ... haematologica 102 (8), 1304, 2017 | 191 | 2017 |
| Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre‐ribosomal RNA processing defect in diamond … HT Gazda, M Preti, MR Sheen, MF O'Donohue, A Vlachos, SM Davies, ... Human mutation 33 (7), 1037-1044, 2012 | 190 | 2012 |
| Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study AT Taher, J Porter, V Viprakasit, A Kattamis, S Chuncharunee, ... Blood, The Journal of the American Society of Hematology 120 (5), 970-977, 2012 | 172 | 2012 |
| Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with â-thalassemia major DJ Pennell, JB Porter, MD Cappellini, LL Chan, A El-Beshlawy, Y Aydinok, ... haematologica 97 (6), 842, 2012 | 156 | 2012 |
| Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion J Calado, Y Sznajer, D Metzger, A Rita, MC Hogan, A Kattamis, M Scharf, ... Nephrology Dialysis Transplantation 23 (12), 3874-3879, 2008 | 147 | 2008 |
| The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets CM Van Tilburg, E Pfaff, KW Pajtler, KPS Langenberg, P Fiesel, BC Jones, ... Cancer discovery 11 (11), 2764-2779, 2021 | 130 | 2021 |
| Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial A Kattamis, V Ladis, H Berdousi, NL Kelekis, E Alexopoulou, ... Blood Cells, Molecules, and Diseases 36 (1), 21-25, 2006 | 127 | 2006 |
| Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study S Mukkada, N Bhakta, GL Chantada, Y Chen, Y Vedaraju, L Faughnan, ... The Lancet Oncology 22 (10), 1416-1426, 2021 | 116 | 2021 |
| R2 relaxometry with MRI for the quantification of tissue iron overload in â‐thalassemic patients E Alexopoulou, F Stripeli, P Baras, I Seimenis, A Kattamis, V Ladis, ... Journal of Magnetic Resonance Imaging: An Official Journal of the …, 2006 | 114 | 2006 |
| Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with â‐thalassemia major O Papakonstantinou, E Alexopoulou, N Economopoulos, O Benekos, ... Journal of Magnetic Resonance Imaging: An Official Journal of the …, 2009 | 113 | 2009 |
| Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel V Di Marco, M Capra, E Angelucci, C Borgna-Pignatti, P Telfer, P Harmatz, ... Blood, The Journal of the American Society of Hematology 116 (16), 2875-2883, 2010 | 112 | 2010 |
